Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi (marstacimab ...

The FDA has updated its warnings about potential cardiac risks associated with Pfizer and Moderna COVID-19 vaccines, ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Pfizer has discontinued its Phase 1b/2 trial of maplirpacept (PF-07901801), a CD47-blocking agent, in combination with ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer Inc. is actively advancing its ...

PORTLAND, OR, UNITED STATES, July 3, 2025 /EINPresswire.com/ -- (Global value: USD 5.4 billion (2021) → USD 7.9 billion (2031) | CAGR 3.8 %) The growth of paresthesia treatment market share is driven ...